Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,011 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators. Ramos F, et al. Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31. Leuk Res. 2015. PMID: 25601157
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
Triguero A, Xicoy B, Zamora L, Jiménez MJ, García O, Calabuig M, Díaz-Beyá M, Arzuaga J, Ramos F, Medina A, Bernal T, Talarn C, Coll R, Collado R, Chen TH, Borrás J, Brunet S, Marchante I, Marco V, López-Cadenas F, Calbacho M, Simiele A, Cortés M, Cedena MT, Pedreño M, Aguilar C, Pedró C, Fernández M, Stoica C, Ribera JM, Sanz G. Triguero A, et al. Among authors: ramos f. Leuk Res. 2022 May;116:106836. doi: 10.1016/j.leukres.2022.106836. Epub 2022 Mar 26. Leuk Res. 2022. PMID: 35405632
Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia.
Chillón MC, Gómez-Casares MT, López-Jorge CE, Rodriguez-Medina C, Molines A, Sarasquete ME, Alcoceba M, Miguel JD, Bueno C, Montes R, Ramos F, Rodríguez JN, Giraldo P, Ramírez M, García-Delgado R, Fuster JL, González-Díaz M, Menendez P. Chillón MC, et al. Among authors: ramos f. Leukemia. 2012 Nov;26(11):2360-6. doi: 10.1038/leu.2012.161. Epub 2012 Jun 18. Leukemia. 2012. PMID: 22705992
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Sanz MA, et al. Blood. 2010 Jun 24;115(25):5137-46. doi: 10.1182/blood-2010-01-266007. Epub 2010 Apr 14. Blood. 2010. PMID: 20393132 Free article. Clinical Trial.
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.
Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups. Barragán E, et al. Haematologica. 2011 Oct;96(10):1470-7. doi: 10.3324/haematol.2011.044933. Epub 2011 Jun 17. Haematologica. 2011. PMID: 21685470 Free PMC article.
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.
Sanz MA, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, Bolufer P, Barragán E, Terol MJ, González JD, Colomer D, Chillón C, Rivas C, Gómez T, Ribera JM, Bornstein R, Román J, Calasanz MJ, Arias J, Alvarez C, Ramos F, Debén G. Sanz MA, et al. Among authors: ramos f. Blood. 1999 Nov 1;94(9):3015-21. Blood. 1999. PMID: 10556184 Free article. Clinical Trial.
The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome.
Cordoba I, Gonzalez-Porras JR, Such E, Nomdedeu B, Luño E, de Paz R, Carbonell F, Vallespi T, Ardanaz M, Ramos F, Marco V, Bonanad S, Sanchez-Barba M, Costa D, Bernal T, Sanz GF, Cañizo MC. Cordoba I, et al. Among authors: ramos f. Leuk Res. 2012 Mar;36(3):287-92. doi: 10.1016/j.leukres.2011.10.025. Epub 2011 Nov 30. Leuk Res. 2012. PMID: 22133642
Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.
San Miguel JF, Vidriales MB, López-Berges C, Díaz-Mediavilla J, Gutiérrez N, Cañizo C, Ramos F, Calmuntia MJ, Pérez JJ, González M, Orfao A. San Miguel JF, et al. Among authors: ramos f. Blood. 2001 Sep 15;98(6):1746-51. doi: 10.1182/blood.v98.6.1746. Blood. 2001. PMID: 11535507 Free article.
2,011 results